Abgenix to Present At JP Morgan H&Q 21st Annual Healthcare Conference.Business Editors FREMONT, Calif.--(BUSINESS WIRE)--Jan. 6, 2003 Abgenix, Inc. (Nasdaq:ABGX) today announced that it will present at the JP Morgan Morgan, American family of financiers and philanthropists. Junius Spencer Morgan, 1813–90, b. West Springfield, Mass., prospered at investment banking. H&Q 21st Annual Healthcare Conference in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden on Thursday, January 9, 2003 at 10:00am PST PST Paroxysmal supraventricular tachycardia, see there . The presentation will be webcast live and may be accessed by visiting the Abgenix Web site, www.abgenix.com. Raymond Withy with·y adj. 1. Made of or as flexible as withes; tough. 2. Wiry and agile. n. pl. with·ies 1. A rope or band made of withes. 2. a. , Ph.D., president and chief executive officer of Abgenix, will provide a company update and outlook for 2003. About Abgenix Abgenix is a biopharmaceutical company focused on the development and commercialization of human therapeutic antibodies. The company's technology platform, which includes XenoMouse(R) and XenoMax(TM) technologies, enables the rapid generation and selection of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology by building a diversified diversified (di·verˑ·s product portfolio through the development of its own internal proprietary products and through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies. For more information on Abgenix, visit the company's Web site at www.abgenix.com. Statements made in this press release about Abgenix' technologies, product development activities and collaborative arrangements and manufacturing activities, other than statements of historical fact, and about its projected financial results, are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements Capital requirements Financing required for the operation of a business, composed of long-term and working capital plus fixed assets. and the extent and breadth of Abgenix' patent portfolio. Please see Abgenix' public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion